Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftibuten + VNRX-7145
- Development stage
- Phase 1
- Lead developer
- Venatorx Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VNRX-7145 is an orally bioavailable, broad-spectrum boronic acid beta-lactamase inhibitor (BLI) developed by Venatorx Pharmaceuticals. It serves as a prodrug of the active inhibitor VNRX-5232. VNRX-7145 is designed to be administered in combination with a partner beta-lactam antibiotic, specifically ceftibuten, to address the clinical challenge of multi-drug resistant (MDR) Gram-negative bacteria. The compound targets a wide range of beta-lactamases, including Class A (ESBLs, KPC), Class C (AmpC), and Class D (OXA-48) enzymes. By inhibiting these enzymes, VNRX-7145 restores the antibacterial activity of ceftibuten against resistant strains, including Carbapenem-Resistant Enterobacteriaceae (CRE). The combination is primarily being developed as an oral treatment option for complicated urinary tract infections (cUTI) and other serious infections that currently necessitate intravenous therapy.
- Other names
- ceftibuten/VNRX-7145VNRX-7145 + ceftibuten
02
Targets
Class A BL (Class A beta-lactamase)AmpC (AmpC beta-lactamase)OXA (Class D beta-lactamase)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on ceftibuten + VNRX-7145.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftibuten + VNRX-7145.